A Phase 1, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2017
At a glance
- Drugs SM 04690 (Primary)
- Indications Intervertebral disc degeneration
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Samumed
- 18 Dec 2017 According to a Samumed media release, the first patient has been dosed in this trial.
- 07 Aug 2017 Status changed from planning to recruiting.
- 28 Nov 2016 New trial record